A Pharmacokinetic/Pharmacodynamic Drug–Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs

Abstract

Objective: Tofogliflozin is an oral hypoglycemic agent with a novel mechanism of action that reduces blood glucose levels by promoting glucose excretion in urine, achieved by selectively inhibiting sodium-glucose co-transporter 2 (SGLT2). We evaluated the effects of several selected anti-type 2 diabetes mellitus (T2DM) drugs-glimepiride, metformin, sitagliptin, pioglitazone, miglitol, nateglinide, and voglibose-on the pharmacokinetics and pharmacodynamics of tofogliflozin, and the effects of tofogliflozin on the pharmacokinetics of these anti-T2DM drugs in healthy male volunteers.

Methods: A single dose of either tofogliflozin alone, one of the anti-T2DM drugs alone, or co-administration of tofogliflozin and the anti-T2DM drug was administered to 108 healthy men. C_max, AUC_inf, and cumulative urine glucose excretion after co-administration of tofogliflozin and each of the anti-T2DM drugs was evaluated relative to the values of those parameters after administration of each drug alone.

Results: None of the anti-T2DM drugs had any effect on tofogliflozin exposure. Tofogliflozin had no or little effect on the exposure of any anti-T2DM drug. No anti-T2DM drug had any major effect on the cumulative urine glucose excretion induced by tofogliflozin. There were no safety concerns evident after administration of any drug alone or in co-administration.

Conclusions: Neither the pharmacokinetics nor the pharmacodynamics of tofogliflozin was affected by any of the anti-T2DM drugs evaluated in this study, nor was the pharmacokinetics of any of the anti-T2DM drugs affected by tofogliflozin in healthy male volunteers.

Key words

tofogliflozin - SGLT2 inhibitor - anti-T2DM drug - drug–drug interaction - urinary glucose excretion - healthy volunteer

• References

• 1 World Health Organization. Diabetes. Fact sheet N°312. Updated January 2015. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ Accessed December 18 2014
• 2 Rosenbloom AL, Joe JR, Young RS et al. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999; 22: 345-354
• 3 Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013; 12: 153-175
• 4 Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol 2013; 65: 317-327
• 5 Ohtake Y, Sato T, Kobayashi T et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012; 55: 7828-7840
• 6 Suzuki M, Honda K, Fukazawa M et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012; 341: 692-701
• 7 Kaku K, Watada H, Iwamoto Y et al., Tofogliflozin 003 Study Group . Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014; 13: 65
• 8 Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63-71
• 9 Schwab D, Portron A, Backholer Z et al. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [¹⁴C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [¹³C]tofogliflozin in humans. Clin Pharmacokinet 2013; 52: 463-473
• 10 Yamane M, Kawashima K, Yamaguchi K et al. In vitro profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes and recombinant human CYP. Xenobiotica 2015; 45: 230-238
• 11 World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Available from http://www.wma.net/en/30publications/10policies/b3/ Accessed December 18 2014
• 12 Standl E, Schnell O. Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012; 9: 163-169
• 13 U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation 2001. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf Accessed December 18 2014
• 14 Maurer TS, Ghosh A, Haddish-Berhane N et al. Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J 2011; 13: 576-584
• 15 Yamaguchi K, Kato M, Ozawa K et al. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. J Pharm Sci 2012; 101: 4347-4356
• 16 Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519
• 17 Kapur A, O’Connor-Semmes R, Hussey EK et al. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC. BMC Pharmacol Toxicol 2013; 14: 26
• 18 U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations DRAFT GUIDANCE 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf Accessed December 18 2014
• 19 Kimura N, Masuda S, Tanihara Y et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20: 379-386
• 20 Chu XY, Bleasby K, Yabut J et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007; 321: 673-683
• 21 Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. Am Fam Physician 1991; 44: 1651-1658
• 22 Nakamura T, Takebe K, Kudoh K et al. Effect of an alpha-glucosidase inhibitor on intestinal fermentation and faecal lipids in diabetic patients. J Int Med Res 1993; 21: 257-267
• 23 Tanizawa Y, Kaku K, Araki E et al. Tofogliflozin 004 and 005 Study Group. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014; 15: 749-766
• 24 Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 2014; 15: 2565-2585
• 25 Strojek K, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938
• 26 Hermansen K, Kipnes M, Luo E et al. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745
• 27 Marre M, Shaw J, Brändle M et al., LEAD-1 SU study group . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278
• 28 Kasichayanula S, Liu X, Shyu WC et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011; 13: 47-54
• 29 Macha S, Mattheus M, Pinnetti S et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: A randomised, open-label, crossover study. J Diab Res Clin Met 2012; 1: 1-14